Trypanothione Reductase: A Viable Chemotherapeutic Target for Antitrypanosomal and Antileishmanial Drug Design
Drug Target Insights · 2007
DOI: 10.1177/117739280700200007 ↗Kurz gefasst
Fachartikel in der Zeitschrift Drug Target Insights, 2007. Verfasst von M. Omar F. Khan. Die Arbeit wurde bisher 57-mal zitiert (Crossref) und nennt 103 Literaturangaben.
Abstract (Originalsprache)
Trypanosomiasis and leishmaniasis are two debilitating disease groups caused by parasites of Trypanosoma and Leishmania spp. and affecting millions of people worldwide. A brief outline of the potential targets for rational drug design against these diseases are presented, with an emphasis placed on the enzyme trypanothione reductase. Trypanothione reductase was identifi ed as unique to parasites and proposed to be an effective target against trypanosomiasis and leishmaniasis. The biochemical basis of selecting this enzyme as a target, with reference to the simile and contrast to human analogous enzyme glutathione reductase, and the structural aspects of its active site are presented. The process of designing selective inhibitors for the enzyme trypanothione reductase has been discussed. An overview of the different chemical classes of inhibitors of trypanothione reductase with their inhibitory activities against the parasites and their prospects as future chemotherapeutic agents are briefl y revealed.
Zitieren
APA
Khan, M. O. F. (2007). Trypanothione Reductase: A Viable Chemotherapeutic Target for Antitrypanosomal and Antileishmanial Drug Design. Drug Target Insights. https://doi.org/10.1177/117739280700200007
Vancouver
Khan MOF. Trypanothione Reductase: A Viable Chemotherapeutic Target for Antitrypanosomal and Antileishmanial Drug Design. Drug Target Insights. 2007. doi:10.1177/117739280700200007
BibTeX
@article{Khan2007,
author = {Khan, M. Omar F.},
title = {Trypanothione Reductase: A Viable Chemotherapeutic Target for Antitrypanosomal and Antileishmanial Drug Design},
journal = {Drug Target Insights},
year = {2007},
doi = {10.1177/117739280700200007}
}
EUVIMED